Form 10-Q HALOZYME THERAPEUTICS, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Halozyme Therapeutics (HALO) PT Raised to $58 at Leerink Partners
November 1, 2024 7:21 AM EDTLeerink Partners analyst David Risinger raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $58.00 (from $56.00) while maintaining a Market Perform rating.
The analyst comments "Bottom line: We revised our model post-3Q results and bumped our DCF-derived PT from $56 to $58 (we... More
